Related Experiment Video
Updated: Aug 4, 2026

11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
25.2K
Current two EGFR mutations in lung adenocarcinoma - case report
Summary
This case study shows a patient with complex EGFR mutations in non-small cell lung cancer responded well to EGFR TKIs therapy. Complex EGFR mutations may be sensitive to targeted treatments.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard for common EGFR mutations in advanced non-small cell lung cancer (NSCLC).
- The effectiveness of EGFR TKIs for rare and complex EGFR mutations remains unclear.
- Complex EGFR mutations involve multiple genetic alterations, posing treatment challenges.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
9.3K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.5K